These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 21304219)

  • 21. Additional value of CSF amyloid-beta 40 levels in the differentiation between FTLD and control subjects.
    Verwey NA; Kester MI; van der Flier WM; Veerhuis R; Berkhof H; Twaalfhoven H; Blankenstein MA; Scheltens And P; Pijnenburg YA
    J Alzheimers Dis; 2010; 20(2):445-52. PubMed ID: 20164558
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neuropsychiatric correlates of cerebrospinal fluid biomarkers in Alzheimer's disease.
    Skogseth R; Mulugeta E; Jones E; Ballard C; Rongve A; Nore S; Alves G; Aarsland D
    Dement Geriatr Cogn Disord; 2008; 25(6):559-63. PubMed ID: 18536520
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cerebrospinal fluid biomarkers and memory present distinct associations along the continuum from healthy subjects to AD patients.
    Rami L; Fortea J; Bosch B; Solé-Padullés C; Lladó A; Iranzo A; Sánchez-Valle R; Molinuevo JL
    J Alzheimers Dis; 2011; 23(2):319-26. PubMed ID: 21098971
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Biomarkers for Alzheimer's disease: after Alzheimer's disease neuroimaging initiative studies].
    Shoji M
    Brain Nerve; 2012 May; 64(5):497-504. PubMed ID: 22570063
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inverse association between CSF Aβ 42 levels and years of education in mild form of Alzheimer's disease: the cognitive reserve theory.
    Dumurgier J; Paquet C; Benisty S; Kiffel C; Lidy C; Mouton-Liger F; Chabriat H; Laplanche JL; Hugon J
    Neurobiol Dis; 2010 Nov; 40(2):456-9. PubMed ID: 20656030
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cerebrospinal fluid biomarkers in Alzheimer's disease families with PSEN1 mutations.
    Fortea J; Lladó A; Bosch B; Antonell A; Oliva R; Molinuevo JL; Sánchez-Valle R
    Neurodegener Dis; 2011; 8(4):202-7. PubMed ID: 21212633
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cerebrospinal fluid tau, A beta, and phosphorylated tau protein for the diagnosis of Alzheimer's disease.
    Formichi P; Battisti C; Radi E; Federico A
    J Cell Physiol; 2006 Jul; 208(1):39-46. PubMed ID: 16447254
    [TBL] [Abstract][Full Text] [Related]  

  • 28. No association of CSF biomarkers with APOEepsilon4, plaque and tangle burden in definite Alzheimer's disease.
    Engelborghs S; Sleegers K; Cras P; Brouwers N; Serneels S; De Leenheir E; Martin JJ; Vanmechelen E; Van Broeckhoven C; De Deyn PP
    Brain; 2007 Sep; 130(Pt 9):2320-6. PubMed ID: 17586559
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies.
    Parnetti L; Tiraboschi P; Lanari A; Peducci M; Padiglioni C; D'Amore C; Pierguidi L; Tambasco N; Rossi A; Calabresi P
    Biol Psychiatry; 2008 Nov; 64(10):850-5. PubMed ID: 18395699
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CSF and MRI markers independently contribute to the diagnosis of Alzheimer's disease.
    Schoonenboom NS; van der Flier WM; Blankenstein MA; Bouwman FH; Van Kamp GJ; Barkhof F; Scheltens P
    Neurobiol Aging; 2008 May; 29(5):669-75. PubMed ID: 17208336
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Alzheimer's CSF markers in older schizophrenia patients.
    Frisoni GB; Prestia A; Geroldi C; Adorni A; Ghidoni R; Amicucci G; Bonetti M; Soricelli A; Rasser PE; Thompson PM; Giannakopoulos P
    Int J Geriatr Psychiatry; 2011 Jun; 26(6):640-8. PubMed ID: 20872913
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical validation of the Lumipulse G cerebrospinal fluid assays for routine diagnosis of Alzheimer's disease.
    Leitão MJ; Silva-Spínola A; Santana I; Olmedo V; Nadal A; Le Bastard N; Baldeiras I
    Alzheimers Res Ther; 2019 Nov; 11(1):91. PubMed ID: 31759396
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele.
    Sunderland T; Mirza N; Putnam KT; Linker G; Bhupali D; Durham R; Soares H; Kimmel L; Friedman D; Bergeson J; Csako G; Levy JA; Bartko JJ; Cohen RM
    Biol Psychiatry; 2004 Nov; 56(9):670-6. PubMed ID: 15522251
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Validation of Alzheimer's disease CSF and plasma biological markers: the multicentre reliability study of the pilot European Alzheimer's Disease Neuroimaging Initiative (E-ADNI).
    Buerger K; Frisoni G; Uspenskaya O; Ewers M; Zetterberg H; Geroldi C; Binetti G; Johannsen P; Rossini PM; Wahlund LO; Vellas B; Blennow K; Hampel H
    Exp Gerontol; 2009 Sep; 44(9):579-85. PubMed ID: 19539742
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reference measurement procedures for Alzheimer's disease cerebrospinal fluid biomarkers: definitions and approaches with focus on amyloid β42.
    Mattsson N; Zegers I; Andreasson U; Bjerke M; Blankenstein MA; Bowser R; Carrillo MC; Gobom J; Heath T; Jenkins R; Jeromin A; Kaplow J; Kidd D; Laterza OF; Lockhart A; Lunn MP; Martone RL; Mills K; Pannee J; Ratcliffe M; Shaw LM; Simon AJ; Soares H; Teunissen CE; Verbeek MM; Umek RM; Vanderstichele H; Zetterberg H; Blennow K; Portelius E
    Biomark Med; 2012 Aug; 6(4):409-17. PubMed ID: 22917143
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A selected reaction monitoring (SRM)-based method for absolute quantification of Aβ38, Aβ40, and Aβ42 in cerebrospinal fluid of Alzheimer's disease patients and healthy controls.
    Pannee J; Portelius E; Oppermann M; Atkins A; Hornshaw M; Zegers I; Höjrup P; Minthon L; Hansson O; Zetterberg H; Blennow K; Gobom J
    J Alzheimers Dis; 2013; 33(4):1021-32. PubMed ID: 23076076
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cerebrospinal fluid levels of A beta 42 and tau: potential markers of Alzheimer's disease.
    Galasko D
    J Neural Transm Suppl; 1998; 53():209-21. PubMed ID: 9700659
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The diagnostic value of tau protein, beta-amyloid (1-42) and their ratio for the discrimination of alcohol-related cognitive disorders from Alzheimer's disease in the early stages.
    Kapaki E; Liappas I; Paraskevas GP; Theotoka I; Rabavilas A
    Int J Geriatr Psychiatry; 2005 Aug; 20(8):722-9. PubMed ID: 16035118
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quantitative analysis of amyloid beta peptides in cerebrospinal fluid of Alzheimer's disease patients by immunoaffinity purification and stable isotope dilution liquid chromatography/negative electrospray ionization tandem mass spectrometry.
    Oe T; Ackermann BL; Inoue K; Berna MJ; Garner CO; Gelfanova V; Dean RA; Siemers ER; Holtzman DM; Farlow MR; Blair IA
    Rapid Commun Mass Spectrom; 2006; 20(24):3723-35. PubMed ID: 17117458
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Longitudinal study of cerebrospinal fluid levels of tau, A beta1-40, and A beta1-42(43) in Alzheimer's disease: a study in Japan.
    Kanai M; Matsubara E; Isoe K; Urakami K; Nakashima K; Arai H; Sasaki H; Abe K; Iwatsubo T; Kosaka T; Watanabe M; Tomidokoro Y; Shizuka M; Mizushima K; Nakamura T; Igeta Y; Ikeda Y; Amari M; Kawarabayashi T; Ishiguro K; Harigaya Y; Wakabayashi K; Okamoto K; Hirai S; Shoji M
    Ann Neurol; 1998 Jul; 44(1):17-26. PubMed ID: 9667589
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.